Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Current Trends and Future Prospects in Autoantibodies in Liver Diseases
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Current Trends and Future Prospects in Autoantibodies in Liver Diseases

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 25 April 2026 | Viewed by 3096

Special Issue Editor

Prof. Dr. Takashi Himoto

E-Mail Website
Guest Editor
Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Kagawa, Japan
Interests: hepatocellular carcinoma; diagnosis; treatment; precision medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to announce the launch of a Special Issue of Journal of Clinical Medicine entitled “Current Trends and Future Prospects in Autoantibodies in Liver Diseases”. Some autoantibodies are recognized as serological hallmarks of autoimmune liver diseases, including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). Other autoantibodies are present in the sera of patients with viral hepatitis, drug-induced hepatitis, liver failure, alcohol-related diseases, and even hepatocellular carcinoma (HCC). The emergence of several types of autoantibodies may predict disease activity, treatment outcomes, or prognosis in liver diseases. On the other hand, insulin resistance may be associated with the production of autoantibodies. Non-organ-specific autoantibodies including antinuclear antibody (ANA) and smooth muscle antibody (SMA) are often present in the sera of patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

This Special Issue will explore the clinical relevance of autoantibodies in liver diseases and discuss the ongoing progress in autoantibodies in relation to liver diseases. We invite the submission of comprehensive manuscripts, including original research or review articles.

Prof. Dr. Takashi Himoto
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liver-specific autoantibodies
  • non-organ-specific autoantibodies
  • autoimmune liver disease
  • diagnosis
  • disease activity
  • treatment outcome
  • prognosis
  • virus-induced autoimmunity
  • drug-induced autoimmunity

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

22 pages, 1366 KB  
Review
Autoantibodies in Primary Biliary Cholangitis: From Classical Markers to Emerging Targets
by Shima Mimura, Asahiro Morishita, Kyoko Oura, Rie Yano, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Joji Tani, Miwa Tatsuta, Takashi Himoto and Hideki Kobara
J. Clin. Med. 2025, 14(23), 8503; https://doi.org/10.3390/jcm14238503 - 30 Nov 2025
Viewed by 521
Abstract
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive destruction of intrahepatic bile ducts. PBC encompasses several clinical subtypes, including classical AMA-positive PBC (90–95% of cases), AMA-negative PBC (5–10%), and overlap syndromes such as AIH-PBC. These subtypes exhibit distinct [...] Read more.
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by progressive destruction of intrahepatic bile ducts. PBC encompasses several clinical subtypes, including classical AMA-positive PBC (90–95% of cases), AMA-negative PBC (5–10%), and overlap syndromes such as AIH-PBC. These subtypes exhibit distinct serological profiles, with AMA-negative cases often presenting PBC-specific antinuclear antibodies (anti-gp210, anti-sp100) and overlap syndromes demonstrating combined autoantibody patterns characteristic of both conditions. Autoantibodies serve as central biomarkers for diagnosis, prognosis, and understanding disease pathogenesis. This review provides a comprehensive overview of classical and emerging autoantibodies associated with PBC, including AMA-M2, anti-gp210, anti-sp100, anti-KLHL12, and anti-RPL30. We discuss their diagnostic significance across PBC subtypes, pathogenic implications, and potential utility in patient stratification and therapeutic monitoring. Recent evidence suggests that bile acid-induced neoantigen formation, rather than classical loss of immune tolerance, may drive AMA production. Advances in autoantibody profiling, including subclass-specific analysis and multi-marker panels, may pave the way for personalized medicine and improved outcomes in PBC. Full article
(This article belongs to the Special Issue Current Trends and Future Prospects in Autoantibodies in Liver Diseases)
►▼ Show Figures

Figure 1

13 pages, 536 KB  
Review
Autoimmune Hepatitis and Drug-Induced Liver Injury in Japan
by Hiroki Nishikawa, Soo Ki Kim and Akira Asai
J. Clin. Med. 2025, 14(13), 4514; https://doi.org/10.3390/jcm14134514 - 25 Jun 2025
Cited by 1 | Viewed by 2245
Abstract
Autoimmune hepatitis (AIH) is the most common liver disease caused by autoimmunity. In Japan, the number of patients with AIH has been increasing in recent years. AIH develops as a result of the loss of immune tolerance to autoantigens in the liver. Drug-induced [...] Read more.
Autoimmune hepatitis (AIH) is the most common liver disease caused by autoimmunity. In Japan, the number of patients with AIH has been increasing in recent years. AIH develops as a result of the loss of immune tolerance to autoantigens in the liver. Drug-induced liver injury (DILI) is an extremely important cause of liver injury in clinical practice and should always be kept in mind in the differential diagnosis. Recently, DILI caused by immune checkpoint inhibitors has been attracting attention. For the diagnosis of DILI, it is important to carefully exclude other possible causes of liver injury and obtain a detailed history of medications and the timing of their use. On the other hand, drug-induced AIH, like hepatitis, also exists and is clinically important because it is often difficult to differentiate from idiopathic AIH. A solid understanding of the pathogenesis of both AIH and DILI is essential for clinicians. This article provides an overview of AIH and DILI in Japan, including the latest findings. Full article
(This article belongs to the Special Issue Current Trends and Future Prospects in Autoantibodies in Liver Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop